Gabitril Generalized Anxiety Disorder Filing Anticipated Mid-Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon expects the results of Phase III studies supporting the anti-seizure medication for generalized anxiety will be available in Q2.
You may also be interested in...
Cephalon Will Not Seek Gabitril Anxiety Indication In The Near-Term
Phase III trial evaluating tiagabine for treatment of generalized anxiety disorder did not meet primary endpoints.
Cephalon Will Not Seek Gabitril Anxiety Indication In The Near-Term
Phase III trial evaluating tiagabine for treatment of generalized anxiety disorder did not meet primary endpoints.
Cephalon And Barr Reach Patent Settlements For Provigil, Actiq
Barr could gain up to two months of exclusivity for its Actiq generic.